Atrial Septostomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Atrial septostomy is a cardiac catheterisation procedure that creates or enlarges a communication in the interatrial septum — the wall separating the right and left atria — to allow controlled blood mixing between the two upper heart chambers. This controlled interatrial shunt is physiologically necessary in certain congenital heart conditions where oxygenated and deoxygenated blood cannot mix sufficiently to sustain life, or where decompression of the right atrium is urgently required in pulmonary vascular disease.

The two primary techniques are balloon atrial septostomy (BAS, also known as Rashkind septostomy) and blade atrial septostomy. In BAS, a catheter carrying a deflated balloon is advanced through the femoral vein, across the atrial septum via the naturally patent foramen ovale or a trans-septal puncture, into the left atrium. The balloon is inflated and rapidly pulled back, tearing the foramen ovale tissue to create an atrial opening. Blade septostomy uses a retractable blade catheter to incise the septum before balloon dilation and is preferred in older patients with a thicker fibrous septum.

The procedure is performed in a cardiac catheterisation laboratory under fluoroscopic and echocardiographic guidance. In critically ill neonates, BAS can be performed at the ICU bedside under echocardiographic guidance alone. The primary goal in neonatal transposition of the great arteries (TGA) is to bridge the patient to definitive surgical correction (arterial switch operation) within the first two weeks of life. In adults with advanced pulmonary arterial hypertension, it provides palliative right ventricular decompression as a bridge to transplantation.

The classic indication for balloon atrial septostomy is complete transposition of the great arteries (TGA) in the neonate — a condition where the aorta and pulmonary artery are switched, creating two parallel circulations with no mixing. Without a communication at atrial, ductal, or ventricular level, TGA is rapidly fatal. BAS creates an interatrial communication that provides sufficient blood mixing to sustain oxygen delivery until arterial switch surgery. It is also indicated in neonates with hypoplastic left heart syndrome where a restrictive or intact atrial septum causes dangerous elevation of pulmonary venous pressure, and in pulmonary atresia with intact ventricular septum to decompress the right atrium.

In adults, atrial septostomy is used in advanced pulmonary arterial hypertension (PAH) as a palliative procedure to create a right-to-left shunt, thereby decompressing the failing right ventricle and increasing systemic cardiac output — improving exercise capacity and functional class at the cost of mild oxygen desaturation. It serves as a bridge to bilateral lung transplantation when maximal medical therapy (endothelin antagonists, PDE-5 inhibitors, prostacyclins) has been exhausted and the patient remains in WHO functional class III–IV with right heart failure.

In neonates, atrial septostomy is an emergency lifesaving intervention for TGA when echocardiography confirms a restrictive or absent interatrial communication causing haemodynamic compromise — oxygen saturation below 60–65% despite prostaglandin E1 infusion. In this context there are essentially no contraindications, as the procedure is the only available bridge to surgical survival. Neonates with hypoplastic left heart syndrome and a restrictive atrial septum are similarly urgent candidates.

In adults with PAH, candidates are patients in WHO class III–IV with documented right heart failure refractory to optimised combination medical therapy. Pre-procedure right heart catheterisation must confirm that right atrial pressure does not exceed 20 mmHg and that the post-shunt systemic oxygen saturation will remain above 80%, which requires modelling of anticipated shunt size. Severely elevated pulmonary vascular resistance, systolic blood pressure below 90 mmHg, near-syncope at rest, or severe hepatic congestion represent prohibitive risk for this palliative procedure.

Balloon atrial septostomy (Rashkind) is the first-line technique in neonates up to approximately three months of age when the foramen ovale is pliable. Standard balloon diameters of 13–17 mm are used, targeting a final atrial communication of 12–15 mm. The procedure can be completed in under 30 minutes and is safe at the ICU bedside under echocardiographic guidance, avoiding radiation exposure in critically ill newborns.

For older infants, children, and adults with a thickened fibrous septum, blade atrial septostomy (Park blade catheter) makes linear incisions in the fossa ovalis before balloon dilation. Trans-septal needle puncture (Brockenbrough technique) combined with serial static balloon dilation using Inoue or conventional balloons is used for PAH patients, where precise sizing of the resulting defect is essential — typically targeting 6–8 mm to achieve haemodynamic benefit without excessive desaturation. Radiofrequency perforation-assisted septostomy is available at specialised centres for severely fibrotic septa. All approaches are performed under combined fluoroscopic and transesophageal or intracardiac echocardiographic guidance. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

In neonates with TGA, BAS reliably improves systemic arterial oxygen saturation from critical levels (40–60%) to acceptable ranges (70–85%) within minutes, providing haemodynamic stabilisation that allows survival to arterial switch surgery. Over 95% of procedures achieve the target atrial communication, with procedural mortality below 1% at experienced centres. Neonates who are stabilised by BAS and undergo timely arterial switch surgery have excellent long-term outcomes, with survival rates above 95% at 10 years.

In PAH, published series demonstrate that atrial septostomy improves right atrial pressure, cardiac output index, and six-minute walk distance in approximately 65–70% of selected patients. The SPADES observational registry showed that patients who underwent atrial septostomy had longer transplant-free survival compared to maximal medical therapy alone in advanced PAH. Haemodynamic improvements are typically maintained for six to twelve months before progressive pulmonary vascular disease erodes the benefit.

In neonates, procedural risks include cardiac perforation (less than 0.5%), arrhythmia during catheter manipulation, mitral valve chordal injury during balloon pullback, and air embolism if the balloon is not completely de-aired before inflation. Haemodynamic deterioration can occur if the communication created is unexpectedly large, causing excessive right-to-left shunting. Real-time echocardiographic monitoring allows immediate detection and management.

In adults with PAH, the principal risk is systemic oxygen desaturation below safe thresholds if the atrial communication exceeds the patient's haemodynamic tolerance, which can be fatal in borderline cases. Contemporary series with rigorous selection report procedural mortality of 1–3%. Trans-septal puncture adds the risk of aortic root or posterior left atrial wall perforation. Long-term concerns include re-stenosis of the atrial communication requiring repeat septostomy in approximately 15–20% at one year, and progressive right-to-left shunting as the pulmonary vascular disease progresses.

In neonates with TGA, post-BAS management occurs in the cardiac ICU with continuous monitoring, prostaglandin E1 infusion to maintain ductal patency, and daily echocardiography to assess the atrial communication and pulmonary anatomy. Arterial switch surgery is planned within the first two weeks. Following surgery, lifelong cardiac follow-up includes annual echocardiography to monitor coronary artery ostia, neo-aortic valve, right ventricular outflow tract, and ventricular function.

In adults with PAH post-atrial septostomy, ICU monitoring for 48–72 hours assesses haemodynamic response and oxygen saturation. Repeat right heart catheterisation at 48 hours quantifies the haemodynamic benefit. Discharge is possible within three to five days when stable. Pulmonary hypertension clinic review occurs every three months, with echocardiography, six-minute walk test, and BNP levels used to track disease progression and shunt adequacy.

As an emergency neonatal intervention, atrial septostomy in developed countries is covered by national health insurance or state funding. In the United States, neonatal cardiac catheterisation including BAS costs USD 15,000–30,000, and the full TGA management package (BAS plus arterial switch) can total USD 150,000–250,000 in hospital charges. For uninsured patients or families from lower-income countries seeking advanced paediatric cardiac care, internationally accredited paediatric cardiac centres offer significant savings.

At high-volume paediatric cardiac programmes in India (Narayana Hrudayalaya, AIIMS, Apollo), the total cost of neonatal TGA management including septostomy, arterial switch surgery, and ICU care is approximately USD 8,000–15,000 — representing 80–90% savings versus US prices. These centres have NABH or JCI accreditation and report outcomes comparable to international benchmarks. For adult PAH atrial septostomy in elective settings, costs in India and Thailand are approximately USD 5,000–10,000 versus USD 20,000–40,000 in the US.

In complete TGA, there is no effective alternative to atrial septostomy as an immediate bridge — prostaglandin E1 alone is insufficient for prolonged stabilisation, and the historical open surgical Blalock-Hanlon atrial septectomy has been entirely superseded by balloon catheter techniques. Definitive treatment is the arterial switch operation, with BAS serving as the essential bridge.

For pulmonary arterial hypertension, atrial septostomy is considered only after optimisation of combination medical therapy with endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogues fails to achieve acceptable functional status. Bilateral lung transplantation or heart-lung transplantation remains the definitive curative option for end-stage PAH, and atrial septostomy should be viewed as a bridge strategy in patients awaiting transplantation rather than a standalone long-term treatment. Pulmonary artery denervation is an emerging investigational technique that may provide haemodynamic benefit in some PAH patients.